Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP) received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense for lead candidate AP-SA02, raising the award total to $28.7 million.

The funds support Phase 3 readiness of intravenous AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA, with plans to initiate a Phase 3 superiority study in the second half of 2026.

Positive

• Additional $2.5 million non-dilutive DoD funding for AP-SA02
• Total DoD award for AP-SA02 increases to $28.7 million
• Funding earmarked to support Phase 3 readiness activities for AP-SA02

Negative

• None.

News Market Reaction – ARMP

+2.04%

4 alerts

+2.04% Session close to close

+5.1% Peak Tracked

-15.2% Trough Tracked

$271.66M Market Cap

1.4x Rel. Volume

In the Jun 23 session, ARMP gained 2.04%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -15.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds $2.5M in non‑dilutive DoD funding, bringing AP‑SA02 support to $28.7M and bac...

Analysis

This announcement adds $2.5M in non‑dilutive DoD funding, bringing AP‑SA02 support to $28.7M and backing Phase 3 readiness. Prior filings highlight going‑concern and funding needs, so future trial initiation timing and capital plans remain key watch points.

Key Figures

Additional DoD funding: $2.5 million Total DoD funding: $28.7 million Planned trial phase: Phase 3 +1 more

4 metrics

Additional DoD funding $2.5 million Incremental non-dilutive award to support AP-SA02 Phase 3 readiness

Total DoD funding $28.7 million Cumulative non-dilutive Department of Defense support for AP-SA02 program

Planned trial phase Phase 3 Superiority study of intravenous AP-SA02 in complicated SAB

Planned start timing Second half of 2026 Target initiation window for Phase 3 AP-SA02 superiority study

Historical Context

5 past events · Latest: May 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Q1 2026 earnings	Negative	-7.0%	Wider net loss and limited cash while preparing costly Phase 3 program.
May 07	Fast Track status	Positive	+1.0%	FDA Fast Track designation for AP-SA02 bacteriophage therapy in SAB.
May 04	Scientific publication	Positive	+10.8%	Peer‑reviewed cryo‑EM data supporting AP-PA02 phage cocktail design.
Apr 27	Board appointment	Neutral	-14.9%	Addition of commercial expert to board for future product launches.
Mar 25	FY 2025 earnings	Negative	+8.6%	Large net loss and going‑concern language despite continued pipeline progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past news shows mixed reactions, with positive clinical updates rewarded while financial and corporate events elicit inconsistent price responses.

Key Terms

bacteriophage therapeutics, methicillin-sensitive s. aureus, mrsa, phase 3, +1 more

5 terms

bacteriophage therapeutics medical

"focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment"

Bacteriophage therapeutics are medicines made from viruses that specifically infect and kill bacteria; think of them as guided missiles that seek out harmful bacteria rather than blanket antibiotics that act like area bombs. They matter to investors because they offer a potential solution to antibiotic resistance and could open new markets, but they also carry development and regulatory uncertainty, complex manufacturing needs, and reimbursement risk that can affect commercial prospects.

methicillin-sensitive s. aureus medical

"bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant"

A common type of bacteria, methicillin-sensitive Staphylococcus aureus (MSSA) can cause infections ranging from minor skin boils to serious bloodstream or lung infections, and it is treatable with standard antibiotics. Investors care because the prevalence, treatment costs, and antibiotic options for MSSA affect healthcare spending, hospital demand, drug sales and regulatory decisions for new antibiotics or diagnostics—similar to how a common fault in a product line shapes demand for repairs and replacements.

mrsa medical

"bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA")."

MRSA is a type of common bacteria that has become resistant to many standard antibiotics, causing infections that are harder to treat. Think of it like a weed that no longer responds to the usual weedkiller; it raises the need for stronger medicines, longer hospital stays, and new products or procedures. For investors, MRSA affects healthcare costs, drug and diagnostic demand, regulatory scrutiny, and potential legal or reputational risks for providers and drugmakers.

phase 3 medical

"intended to fund key activities to support Phase 3 readiness of AP-SA02."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

adjunct treatment medical

"AP-SA02, for adjunct treatment of complicated Staphylococcus aureus ("S. aureus") bacteremia"

An adjunct treatment is an additional therapy used alongside a main treatment to improve outcomes, reduce side effects, or address aspects the primary therapy does not cover. Think of it as a supporting player or assistant coach that can enhance the effectiveness of the lead approach. For investors, adjunct treatments matter because they can expand a product’s market, create new revenue streams, influence regulatory decisions, and affect adoption rates and long‑term value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Supports Phase 3 readiness of AP-SA02

Non-dilutive DoD funding totals $28.7M to date

LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $2.5 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The award, which now totals $28.7 million, supports the development of Armata's lead clinical candidate AP-SA02, for adjunct treatment of complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). The additional $2.5 million is intended to fund key activities to support Phase 3 readiness of AP-SA02.

"The DoD has been a strong and valued partner in the development of AP-SA02, and we appreciate its continued support for this important program," said Dr. Deborah Birx, Chief Executive Officer of Armata. "With phage therapy gaining attention globally as a potential tool to combat the growing antimicrobial resistance crisis, DoD support at the federal level is important to ensuring the U.S. contributes to this critical field. We remain focused on moving AP-SA02 efficiently through clinical development with the goal of delivering this novel phage-based therapy to patients in need, including both military and civilian populations."

"Armata is advancing plans to initiate a Phase 3 superiority study of intravenous AP-SA02 in complicated SAB in the second half of 2026. Principal Investigators at sites around the U.S. continue to express excitement about participating in the Phase 3 study. We believe AP-SA02 has the potential to bring new hope to all patients affected by this common, highly severe, and often deadly infection," concluded Dr. Birx.

About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated SAB caused by MSSA or MRSA. AP-SA02 has received Qualified Infectious Disease Product (QIDP) and Fast Track  designations from the U.S. Food and Drug Administration. Armata's diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated SAB. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025.

About Armata Pharmaceuticals, Inc.

Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic, including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements

This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:

Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-receives-2-5-million-of-additional-non-dilutive-award-funding-from-the-us-department-of-defense-to-support-ap-sa02--302807082.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

What did Armata (NYSE American: ARMP) announce about DoD funding for AP-SA02 on June 23, 2026?

Armata announced an additional $2.5 million in non-dilutive U.S. DoD funding for AP-SA02. According to Armata, this raises the total Department of Defense award supporting the program to $28.7 million to advance development of its phage-based therapy for complicated Staphylococcus aureus bacteremia.

How much total non-dilutive DoD funding has Armata received for AP-SA02 (ARMP)?

Armata has received a total of $28.7 million in non-dilutive DoD funding for AP-SA02. According to Armata, this funding flows through MTEC and is managed by Naval Medical Research Command to support clinical development and Phase 3 readiness activities.

What is AP-SA02 and which infection is Armata (ARMP) targeting?

AP-SA02 is Armata’s lead phage-based clinical candidate targeting Staphylococcus aureus bacteremia. According to Armata, it is being developed as adjunct intravenous treatment for complicated S. aureus bloodstream infections caused by methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains, which are often severe and difficult to treat.

How will the new $2.5 million DoD funding support AP-SA02 Phase 3 readiness for Armata?

The $2.5 million will fund key activities required for Phase 3 readiness of AP-SA02. According to Armata, these funds are intended to prepare for a planned Phase 3 superiority study of intravenous AP-SA02 in complicated Staphylococcus aureus bacteremia patients.

When does Armata Pharmaceuticals (ARMP) plan to start the Phase 3 study of AP-SA02?

Armata plans to initiate a Phase 3 superiority study of intravenous AP-SA02 in the second half of 2026. According to Armata, the trial will evaluate AP-SA02 as adjunct treatment in patients with complicated Staphylococcus aureus bacteremia at clinical sites across the United States.

Why is the U.S. Department of Defense funding Armata’s AP-SA02 phage therapy program?

The DoD is funding AP-SA02 as part of efforts to address antimicrobial resistance in serious infections. According to Armata, support through MTEC and Naval Medical Research Command reflects federal interest in phage therapy to aid both military and civilian patients with difficult-to-treat bacterial infections.